Skip to Main Content

For healthcare professionals

About us Opens in new tab

US website Opens in new tab

Contact Opens in new tab

InOncology

Oncology pipeline
Oncology pipeline

Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell–directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches.

Section overview

Oncology pipeline

Section overview

HER2 TKI – zongertinib

DLL3/CD3 T-cell engager – obrixtamig

B7-H6/CD3 T-cell engager

CD137xFAP bsAb

SIRPα antagonist

VSV-GP oncolytic virus

2^nd generation STING agonist

PD-1 inhibitor – ezabenlimab
Tumor types in focus
Tumor types in focus

Get an overview of different cancer types and how recent advances may affect clinical decision making and treatment of these cancers.

Section overview

Tumor types in focus

Section overview

Non-small cell lung cancer

Small cell lung cancer

Gastrointestinal cancers

Head and neck squamous cell carcinoma

Breast cancer
Collaborations
Collaborations

We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

Collaborations

Collaborations

opnMe Opens in new tab
Congress publications Opens in new tab
About us Opens in new tab
US website Opens in new tab
Contact Opens in new tab

InOncology

Sitemap

Name: Sitemap
Keywords: Sitemap

Oncology pipeline

Tumor types in focus

Collaborations
- Collaborations
- opnMe Opens in new tab

Congress publications Opens in new tab

Home
Sitemap

Terms of useOpens in new tab
Sitemap
Imprint Opens in new tab
Privacy notice Opens in new tab

InOncology

Pipeline compounds shown in this website are under pre-clinical and/or clinical investigation and have not been approved by regulatory authorities for commercial use in patients. Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the uses under investigation.
© 2026 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: March 2026